Research Article
DNA Primase Subunit 1 Expression in Hepatocellular Carcinoma and Its Clinical Implication
Table 1
TCGA hepatocellular carcinoma patient characteristics.
| Clinical factors | Total () | % |
| Sex | | | Male | 243 | 67.5 | Female | 117 | 32.5 | BMI (kg/m2) | | | <18.5 | 21 | 6.4 | 18.5~24.99 | 152 | 46.5 | 25-29.99 | 87 | 26.6 | >30 | 67 | 20.5 | Stage | | | I | 167 | 49.7 | II | 81 | 24.1 | III | 84 | 25.0 | IV | 4 | 1.2 | Grade | | | G1 | 53 | 14.9 | G2 | 171 | 48.2 | G3 | 120 | 33.8 | G4 | 11 | 3.1 | Age at diagnosis (y) | | | <55 | 113 | 30.0 | ≥55 | 247 | 70.0 | AFP (ng/ml) | | | ≤400 | 207 | 76.7 | >400 | 63 | 23.3 | Platelet (103/mm3) | 24.1 (0.004-499) | | Race | | | Asian | 155 | 44.3 | White | 176 | 50.3 | Black or African American | 17 | 4.9 | American Indian or Alaska Native | 2 | 0.6 |
|
|
Note: TCGA: The Cancer Genome Atlas; BMI: body mass index; AFP: alpha-fetoprotein.
|